Lixisenatide
Lixisenatide is a peptide, indexed here under Incretin receptor agonists.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Incretin receptor agonists |
| CAS registry number | 320367-13-3[1] |
| PubChem CID | 90472060[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C215H347N61O65S[1] |
| Molecular weight | 4858 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Lixisenatide is a once-daily GLP-1 receptor agonist. The Drugs@FDA register returned an approved application for a fixed-ratio combination with insulin glargine under this generic name, recorded in the regulatory status field and not what this page describes. A 2012 Diabetes, Obesity and Metabolism paper reports a randomised double-blind placebo-controlled trial in Asian patients, 2013 Diabetes Care papers report adding once-daily lixisenatide to basal insulin, a 2015 Diabetes Care paper contrasts its effects on postprandial glycaemic control and gastric emptying with liraglutide, and 2016 Diabetes Care papers report the LixiLan fixed-ratio combination with insulin glargine.
Outcome and neuroscience records include the 2015 New England Journal of Medicine ELIXA trial in type 2 diabetes and acute coronary syndrome, a 2018 Lancet Diabetes and Endocrinology exploratory analysis of renal outcomes from that trial, a 2012 BMC Neuroscience paper reporting that liraglutide and lixisenatide cross the blood-brain barrier in a rodent model, a 2015 Neuroscience paper in the MPTP mouse model, and a 2024 New England Journal of Medicine trial in early Parkinson disease.
[3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]Reported mechanism
A once-daily GLP-1 receptor agonist, per the retrieved records, with reported effects on postprandial glycaemic control and gastric emptying.
[3, 6]Stated in the titles of the cited 2012 Diabetes, Obesity and Metabolism and 2015 Diabetes Care papers.
Targets named in the cited records: GLP-1 receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including BLA208673, marketed as SOLIQUA 100/33). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Lixisenatide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- AVE0010
- Adlyxin
- Lyxumia
Where this page sits
Research records
Cited research records for Lixisenatide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Exenatide — Incretin receptor agonists
- Liraglutide — Incretin receptor agonists
Named targets in the cited records
Class page: Incretin receptor agonists. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Lixisenatide?
Lixisenatide is a once-daily GLP-1 receptor agonist. The Drugs@FDA register returned an approved application for a fixed-ratio combination with insulin glargine under this generic name, recorded in the regulatory status field and not what this page describes.
Which class is Lixisenatide indexed under?
Lixisenatide is indexed under Incretin receptor agonists. Incretin receptor agonists are synthetic peptides that bind one or more of the incretin and glucagon family receptors, principally the glucagon-like peptide-1 receptor.
What does the FDA application register show for Lixisenatide?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including BLA208673, marketed as SOLIQUA 100/33). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.
Sources
- PubChem Compound Summary for CID 90472060, Lixisenatide. PubChem, National Library of Medicine (2026). pubchem:90472060
- Drugs@FDA application register query for this compound, 1 application(s) returned: BLA208673. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:lixisenatide
- Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes, obesity & metabolism (2012). pmid:22564709
- Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes care (2013). pmid:23628617
- Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes care (2013). pmid:23564915
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial. Diabetes care (2015). pmid:25887358
- Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes care (2016). pmid:27527848
- Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes care (2016). pmid:27650977
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. The New England journal of medicine (2015). pmid:26630143
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. The lancet. Diabetes & endocrinology (2018). pmid:30292589
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC neuroscience (2012). pmid:22443187
- Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience (2015). pmid:26141845
- Trial of Lixisenatide in Early Parkinson's Disease. The New England journal of medicine (2024). pmid:38598572
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.